Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani,Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi,Damien Ambrosetti,Jerome Durivault,Frederic Luciano,Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger,Rachid Benhida,Lisa Kinget,Benoit Beuselinck,Cyril Ronco,Gilles Pagès,Maeva Dufies

Journal of Experimental & Clinical Cancer Research（2024）

引用 0|浏览3

暂无评分

摘要

In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40

查看译文

关键词

Renal Cell Carcinoma,M2 tumor associated macrophages,Immunotherapies resistance,CXCR2 inhibitors,Nivolumab,Ipilimumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要